Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5449]

Teclistamab continues to demonstrate deep and durable responses in relapsed...

Dr Alfred Garfall - Penn Medicine Abramson Cancer Center, Philadelphia, USA

$Teclistamab continues to demonstrate deep and durable responses in relapsed/refractory multiple myeloma ( Dr Alfred Garfall - Penn Medicine Abramson Cancer Center, Philadelphia, USA )$

Trial argues strongly for the development of 1st-line biomarker selected...

Prof Jennifer Knox - University of Toronto, Toronto, Canada

Trial argues strongly for the development of 1st-line biomarker selected strategies in pancreatic ductal adenocarcinoma ( Prof Jennifer Knox - University of Toronto, Toronto, Canada )

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic...

Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic urothelial cancer across all exposure quartiles ( Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA )

ARV-766 well tolerated and shows promising clinical activity in metastatic...

Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA

ARV-766 well tolerated and shows promising clinical activity in metastatic castration-resistant prostate cancer ( Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA )

ASCO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

ASCO 2024: Latest in mRCC treatment

Dr Sumanta Kumar Pal, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Thomas...

ASCO 2024: Latest in mRCC treatment ( Dr Sumanta Kumar Pal, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Thomas Powles )

ASCO 2024: Advances in NSCLC

Dr Enriqueta Felip, Dr Alex Spira, Dr Antonio Passaro and Dr Alfredo Addeo

ASCO 2024: Advances in NSCLC ( Dr Enriqueta Felip, Dr Alex Spira, Dr Antonio Passaro and Dr Alfredo Addeo )

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed...

Prof Thierry Facon - Chu De Lille, Lille, France

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Thierry Facon - Chu De Lille, Lille, France )

Clinical behaviour of breast cancer in young BRCA carriers and prognostic...

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Clinical behaviour of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible...

Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France )

Durvalumab after chemoradiotherapy improves survival in limited-stage SCLC

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA

Durvalumab after chemoradiotherapy improves survival in limited-stage SCLC ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )

Chemotherapy before and after surgery may be new standard treatment for some...

Prof Jens Hoeppner - University of Bielefeld, Bielefeld, Germany

Chemotherapy before and after surgery may be new standard treatment for some patients with oesophageal cancer ( Prof Jens Hoeppner - University of Bielefeld, Bielefeld, Germany )

More from ecancer